Zhengye Biotechnology Holding (ZYBT) Accumulated Expenses (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Accumulated Expenses for 3 consecutive years, with $488257.4 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Accumulated Expenses fell 37.56% year-over-year to $488257.4 in Q4 2025; TTM through Dec 2025 was $488257.4, a 37.56% decrease from a year earlier, with the FY2025 full-year figure at $495000.0, down 35.63% from the prior year.
• Accumulated Expenses was $488257.4 for Q4 2025 at Zhengye Biotechnology Holding, down from $529000.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $781974.7 in Q4 2024 and troughed at $400273.5 in Q4 2023.
• A 3-year average of $549876.4 and a median of $508628.7 in 2025 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses jumped 95.36% in 2024 and slumped 37.56% in 2025, its largest moves.
• Over 3 years, Accumulated Expenses stood at $400273.5 in 2023, then jumped by 95.36% to $781974.7 in 2024, then tumbled by 37.56% to $488257.4 in 2025.
• The last three Accumulated Expenses figures came in at $488257.4 (Q4 2025), $529000.0 (Q2 2025), and $781974.7 (Q4 2024), per Business Quant data.